Repairon's Engineered Heart Muscle Patches Show Promise in Advanced Heart Failure Trial Published in NEJM
核心洞察
Repairon (搜索)'s BioVAT (搜索)-HF Phase 1-2 trial demonstrated that engineered human heart muscle patches can safely restore heart function in patients with advanced heart failure.
The study showed significant improvements in heart wall thickness, left ventricular ejection fraction, and quality of life scores at 3 and 12 months follow-up.
Results published in the New England Journal of Medicine provide evidence that stem cell-derived heart muscle tissue can integrate with damaged myocardium and contract in synchrony with native tissue.
Repairon (搜索) announced that clinical trial results for its engineered human heart muscle tissue therapy have been published in the New England Journal of Medicine, marking a significant advancement in regenerative cardiac medicine. The BioVAT (搜索)-HF trial demonstrated that restoration of heart muscle function in patients with advanced heart failure is achievable, resulting in improved health and quality of life.
Clinical Trial Design and Patient Population
The BioVAT (搜索)-HF clinical trial was a Phase 1-2 study designed to assess safety and preliminary efficacy of implanting fully functional heart muscle patches onto the weakened left ventricular muscle of patients with advanced heart failure with reduced ejection fraction (HFrEF). The engineered patches were created from human induced pluripotent stem cell-derived terminally differentiated heart muscle cells and administered alongside guideline-directed medical therapy.
The trial enrolled 20 patients and began with a dose-escalation phase to establish the safe maximum dose, followed by treatment at that dose to further evaluate safety and efficacy. Of the enrolled patients, 16 received the safe maximum dose. Follow-up ranged from 6 to 52 months across patients, with the last enrolled patient completing 3 months of follow-up at the time of reporting.
Safety Profile and Adverse Events
The safety analysis revealed that 3 patients died during the trial from causes that the Data Safety Monitoring Board graded as unrelated to the BioVAT (搜索) therapy. Severe adverse events were mostly related to underlying heart and concurrent diseases as well as to immunosuppression requiring adaptation of the immunosuppression regimen.
Three patients experienced episodes of ventricular tachycardia, which were found to be unrelated to the BioVAT (搜索) transplant. Notably, no patients experienced ventricular fibrillation. Among the 16 patients who received the safe maximal dose, only 2 patients required heart failure hospitalizations.
Efficacy Outcomes and Functional Improvements
The efficacy findings demonstrated meaningful improvements across multiple cardiac function parameters for patients who received the safe maximal dose. Target heart wall thickness increased 4.5 mm at 3 months and 2.9 mm at 12 months follow-up compared to baseline. Left ventricular ejection fraction showed progressive improvement, increasing 3.9% at 3 months and 6.9% at the latest timepoint.
Quality of life measurements using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) showed substantial improvements, with increases of 6.7 points at 3 months and 15 points at 12 months follow-up.
Mechanistic Evidence and Tissue Integration
The study outcomes support preclinical findings that engineered heart muscle can integrate with damaged myocardium, form a vascularized layer, and contract in synchrony with native tissue. This was further confirmed through analysis of an explanted heart from a patient in the dose-finding cohort who later underwent cardiac transplantation, providing clear evidence of human heart remuscularization and associated increases in wall thickness, ejection fraction, and quality of life.
Clinical Significance and Future Directions
Wolfram-Hubertus Zimmermann, MD, professor and director of the Institute of Pharmacology and Toxicology at the University Medical Center Goettingen, Germany, and principal author of the NEJM publication, explained the therapeutic rationale: "Heart failure therapies available today can often slow the progression of the disease, but they cannot replace destroyed heart muscle. Our goal, therefore, is to generate new, functional heart muscle tissue and thereby provide targeted support to the weakened heart."
The authors concluded that further clinical investigations with longer follow-up times are warranted based on these encouraging results.
Addressing Critical Medical Need
The therapy addresses a significant unmet medical need, as approximately 5% of the global population suffers from chronic heart failure of any severity, and it remains one of the most common causes of death. In the United States, heart failure represents the most common cause of hospitalization and mortality in the senior population, affecting over 6 million people.
As heart failure progresses to advanced stages, patients experience weakness with discomfort during all physical activities and at rest, sometimes requiring constant bed rest. For these severely ill patients, the only treatment options currently available are mechanical pump devices or heart transplantation.
Lothar Germeroth, Ph.D., Repairon (搜索)'s CEO, emphasized the potential impact: "We are highly encouraged by these Phase II results, which we believe validate the therapeutic potential of our regenerative cardiac patch platform. Heart failure remains one of the leading causes of morbidity and mortality worldwide, and we believe these findings may open a new chapter in myocardial regeneration and restorative cardiovascular medicine."